The FREND™ System is an in vitro diagnostic device that uses microfluidics technology and immunofluorescent techniques.
Disposable plastic microfluid chip continuously mixes, reacts, separates, and quantitative analysis on the chip.
This is a source technology that is the foundation for bioengineering experiments and point-of-care test (POCT). FDA 510(k) cleared device.
Recommended use at a minimum of 8 days after the onset of symptoms for accurate antibody test results.
Sample of 381 specimens, 8 days after symptom onset using the FREND System resulted in ~100% PPA (positive percent agreement); 97% NPA (negative percent agreement).
